438 related articles for article (PubMed ID: 30241990)
1. A potential role for adjunctive omega-3 polyunsaturated fatty acids for depression and anxiety symptoms in recent onset psychosis: Results from a 16 week randomized placebo-controlled trial for participants concurrently treated with risperidone.
Robinson DG; Gallego JA; John M; Hanna LA; Zhang JP; Birnbaum ML; Greenberg J; Naraine M; Peters BD; McNamara RK; Malhotra AK; Szeszko PR
Schizophr Res; 2019 Feb; 204():295-303. PubMed ID: 30241990
[TBL] [Abstract][Full Text] [Related]
2. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal investigation of the relationship between omega-3 polyunsaturated fatty acids and neuropsychological functioning in recent-onset psychosis: A randomized clinical trial.
Szeszko PR; McNamara RK; Gallego JA; Malhotra AK; Govindarajulu U; Peters BD; Robinson DG
Schizophr Res; 2021 Feb; 228():180-187. PubMed ID: 33444934
[TBL] [Abstract][Full Text] [Related]
4. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis.
Crespo-Facorro B; Pérez-Iglesias R; Ramirez-Bonilla M; Martínez-García O; Llorca J; Luis Vázquez-Barquero J
J Clin Psychiatry; 2006 Oct; 67(10):1511-21. PubMed ID: 17107241
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive Taurine in First-Episode Psychosis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study.
O'Donnell CP; Allott KA; Murphy BP; Yuen HP; Proffitt TM; Papas A; Moral J; Pham T; O'Regan MK; Phassouliotis C; Simpson R; McGorry PD
J Clin Psychiatry; 2016 Dec; 77(12):e1610-e1617. PubMed ID: 27835719
[TBL] [Abstract][Full Text] [Related]
6. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
7. Effect of ω-3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders: The NEURAPRO Randomized Clinical Trial.
McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EY; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Amminger GP
JAMA Psychiatry; 2017 Jan; 74(1):19-27. PubMed ID: 27893018
[TBL] [Abstract][Full Text] [Related]
8. A 16-week randomized placebo-controlled trial investigating the effects of omega-3 polyunsaturated fatty acid treatment on white matter microstructure in recent-onset psychosis patients concurrently treated with risperidone.
Lyall AE; Nägele FL; Pasternak O; Gallego JA; Malhotra AK; McNamara RK; Kubicki M; Peters BD; Robinson DG; Szeszko PR
Psychiatry Res Neuroimaging; 2021 Jan; 307():111219. PubMed ID: 33221631
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Comparison of Aripiprazole and Risperidone for the Acute Treatment of First-Episode Schizophrenia and Related Disorders: 3-Month Outcomes.
Robinson DG; Gallego JA; John M; Petrides G; Hassoun Y; Zhang JP; Lopez L; Braga RJ; Sevy SM; Addington J; Kellner CH; Tohen M; Naraine M; Bennett N; Greenberg J; Lencz T; Correll CU; Kane JM; Malhotra AK
Schizophr Bull; 2015 Nov; 41(6):1227-36. PubMed ID: 26338693
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms.
Hamner MB; Faldowski RA; Ulmer HG; Frueh BC; Huber MG; Arana GW
Int Clin Psychopharmacol; 2003 Jan; 18(1):1-8. PubMed ID: 12490768
[TBL] [Abstract][Full Text] [Related]
11. A prospective comparative study of risperidone long-acting injectable for treatment-resistant schizophrenia with dopamine supersensitivity psychosis.
Kimura H; Kanahara N; Komatsu N; Ishige M; Muneoka K; Yoshimura M; Yamanaka H; Suzuki T; Komatsu H; Sasaki T; Hashimoto T; Hasegawa T; Shiina A; Ishikawa M; Sekine Y; Shiraishi T; Watanabe H; Shimizu E; Hashimoto K; Iyo M
Schizophr Res; 2014 May; 155(1-3):52-8. PubMed ID: 24667073
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial.
Howard R; Cort E; Bradley R; Harper E; Kelly L; Bentham P; Ritchie C; Reeves S; Fawzi W; Livingston G; Sommerlad A; Oomman S; Nazir E; Nilforooshan R; Barber R; Fox C; Macharouthu AV; Ramachandra P; Pattan V; Sykes J; Curran V; Katona C; Dening T; Knapp M; Gray R;
Lancet Psychiatry; 2018 Jul; 5(7):553-563. PubMed ID: 29880238
[TBL] [Abstract][Full Text] [Related]
13. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.
Amminger GP; Schäfer MR; Papageorgiou K; Klier CM; Cotton SM; Harrigan SM; Mackinnon A; McGorry PD; Berger GE
Arch Gen Psychiatry; 2010 Feb; 67(2):146-54. PubMed ID: 20124114
[TBL] [Abstract][Full Text] [Related]
14. Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders - Results from a double-blind, randomized and placebo-controlled clinical trial.
Jahangard L; Sadeghi A; Ahmadpanah M; Holsboer-Trachsler E; Sadeghi Bahmani D; Haghighi M; Brand S
J Psychiatr Res; 2018 Dec; 107():48-56. PubMed ID: 30317101
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
Citrome L; Meng X; Hochfeld M; Stahl SM
Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.
Kelly DL; Sullivan KM; McEvoy JP; McMahon RP; Wehring HJ; Gold JM; Liu F; Warfel D; Vyas G; Richardson CM; Fischer BA; Keller WR; Koola MM; Feldman SM; Russ JC; Keefe RS; Osing J; Hubzin L; August S; Walker TM; Buchanan RW
J Clin Psychopharmacol; 2015 Aug; 35(4):374-81. PubMed ID: 26082974
[TBL] [Abstract][Full Text] [Related]
17. Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial.
Kashani L; Shams N; Moazen-Zadeh E; Karkhaneh-Yousefi MA; Sadighi G; Khodaie-Ardakani MR; Rezaei F; Rahiminejad F; Akhondzadeh S
J Psychiatr Res; 2017 Nov; 94():70-77. PubMed ID: 28688338
[TBL] [Abstract][Full Text] [Related]
18. Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up.
Kimura H; Kanahara N; Sasaki T; Komatsu N; Ishige M; Muneoka K; Ino H; Yoshimura K; Yamanaka H; Suzuki T; Komatsu H; Watanabe H; Shimizu E; Iyo M
J Psychopharmacol; 2016 Aug; 30(8):795-802. PubMed ID: 27371496
[TBL] [Abstract][Full Text] [Related]
19. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
[TBL] [Abstract][Full Text] [Related]
20. Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.
Takahashi H; Kamata M; Yoshida K; Ishigooka J; Higuchi H
J Clin Psychiatry; 2006 Oct; 67(10):1577-82. PubMed ID: 17107250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
